Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04141 (
granulocyte-macrophage colony-stimulating factor
)
6,790
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
T cell-derived cytokines, such as interleukin-5 (IL-5) and
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) activate eosinophils, whereas other cytokines, such as tumor necrosis factor (TNF)-alpha and IL-13, determine eosinophil recruitment. Interferon-alpha (IFN-alpha), a leukocyte-derived cytokine, has been shown to have beneficial effects in eosinophil-mediated disorders, such as the hypereosinophilic syndrome and a murine model of allergic asthma, where it inhibited eosinophil recruitment. We tested the hypothesis that
IFN
-alpha acted in eosinophil-mediated disorders by modulating T cell cytokine expression. Peripheral blood mononuclear cells (PBMC) or human ragweed-specific TH1 (2B8) and TH2 (2D2) T cell clones were cultured in the presence of 5 micrograms/ml of phytohemagglutinin (PHA) or 25 micrograms/ml of antigen Amb a 1 (short ragweed allergen), respectively, and lymphoblastoid
IFN
-alpha (varying from 0 to 10,000 U/ml). We assessed T cell proliferation by [3H]thymidine incorporation and production of IL-5 and
GM-CSF
by ELISA. Expression of cytokine transcripts was analyzed by the reverse transcription-polymerase chain reaction technique (RT-PCR).
IFN
-alpha induced a dose-dependent suppression of T cell proliferation of both PBMC (p < 0.001) and the T cell clones (p < 0.001).
IFN
-alpha inhibited gene expression of IL-5,
GM-CSF
, TNF-alpha, and IL-13 in PBMC. Furthermore,
IFN
-alpha significantly inhibited mitogen-induced and antigen-induced production of IL-5 and
GM-CSF
.
IFN
-alpha may benefit eosinophil-mediated disorders by inhibiting T cell function and production of cytokines active on human eosinophils.
...
PMID:Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. 891 Jul 67
Activation of human blood neutrophils and monocytes for enhanced release of toxic oxygen radicals may take place after priming with several cytokines including hematopoietic growth factors. The potential impact of human immunodeficiency virus (HIV) on this response and the relative potency of various cytokines remains unclear. Blood neutrophils and monocytes were isolated from 25 HIV outpatients with variable immunodeficiency. Oxidative burst response upon stimulation with N-formyl-methionyl-leucyl-phenylalanine was assessed in neutrophils after priming with granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) and interferon-gamma (IFN-g), and in monocytes after priming with
GM-CSF
and
IFN
-g. Monocyte oxidative burst responses were not changed in patients or controls. In contrast, following priming with
IFN
-g,
GM-CSF
or medium (but not G-CSF) the neutrophils in HIV patients with CD4 counts > 200 x 10(9)/L exhibited a significantly higher chemiluminescence response than was seen in healthy age-matched controls, whereas the response in patients with lower CD4 counts was not different from controls. At comparable concentrations,
GM-CSF
induced a significantly higher priming than G-CSF and
IFN
-g. A significant positive correlation between CD4 counts and priming activity of
GM-CSF
and
IFN
-g on neutrophils was observed. We conclude that neutrophils in HIV infection have a normal or enhanced response to the oxidative metabolism priming activity of hematopoietic growth factors in vitro, whereas priming effect on monocytes was not seen.
...
PMID:Priming of neutrophil and monocyte activation in human immunodeficiency virus infection. Comparison of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and interferon-gamma. 897 88
The safety and efficacy of
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) as adjuvant therapy for interferon alpha (IFN-alpha) treatment has been evaluated in 20 non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. Adjuvant therapy with
GM-CSF
plus
IFN
-alpha was associated with less myelosuppression than with
IFN
-alpha alone (P < .01), although the rate of local adverse reactions increased.
GM-CSF
adjuvant therapy led to a 50% biochemical response (transaminase values within the normal range at therapy end) and to reductions in HCV RNA concentrations (median HCV RNA reduction of 99%, range 8-100%), which were similarly observed in single
IFN
-alpha recipients (median HCV RNA reduction of 91%, range 38-100%). However, HCV RNA became undetectable in three biochemical responders to the
GM-CSF
adjuvant therapy, but in only one biochemical non-responder to
IFN
-alpha alone. The use of
GM-CSF
as adjuvant therapy is safe and, although it has not improved the biochemical response, it might potentiate the virologic response to
IFN
-alpha treatment alone.
...
PMID:Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for factor as adjuvant therapy for interferon alpha treatment of chronic hepatitis C. 916 22
Three experiments tested the effects of recombinant bovine
granulocyte-macrophage colony-stimulating factor
(rbGM-CSF) on the preimplantation bovine and ovine conceptus. There was no effect of rbGM-CSF on the secretion of total radiolabeled protein in conditioned medium, immunoreactive interferon-tau (
IFN
tau), antiviral activity, or prostaglandin E2 from Day 16-18 bovine conceptuses cultured for 24 hr with, [3H]leucine and +/- 10 ng/ml rbGM-CSF. Similarly, there was no effect of 1 ng/ml rbGM-CSF on the secretion of total radiolabeled protein.
IFN
tau, or antiviral activity from Day 17 ovine conceptuses. There was also no beneficial effect of 1 or 10 ng/ml rbGM-CSF on the presence of immunoreactive
IFN
tau in conditioned medium from in vitro-produced bovine blastocysts at Day 7-8 after fertilization. Results indicate that
IFN
tau secretion from bovine and ovine conceptuses are unresponsive to rbGM-CSF at the concentrations tested.
...
PMID:Lack of effect of granulocyte-macrophage colony-stimulating factor on secretion of interferon-tau, other proteins, and prostaglandin E2 by the bovine and ovine conceptus. 917 77
The interferon-alpha and -beta (
IFN
-alpha/beta) producing ability of the two murine dendritic cell (DC) lines D2SC/1 and FSDC was studied. The D2SC/1 cells produced
IFN
-alpha and -beta when stimulated by herpes simplex virus (HSV), Sendai virus (SV) or by the bacteria Escherichia coli or Staphylococcus aureus Cowan I. Precultivating (priming) D2SC/1 cells with recombinant IFN-beta or a combination of IFN-beta and
granulocyte-macrophage colony-stimulating factor
increased production of
IFN
-alpha/beta induced by HSV or the bacteria, but not by SV. Also, the kinetics of
IFN
-alpha/beta responses were different for SV compared to HSV and the bacteria, suggesting different induction mechanisms. The FSDC cells differed from the D2SC/1 cells mainly in that predominantly IFN-beta was produced, that little or no
IFN
-alpha/beta production was induced by the bacteria, and that the
IFN
-alpha/beta responses were most efficiently primed by IFN-gamma. Priming the DC lines with tumour necrosis factor-alpha, interleukin-10 (IL-10) or IL-4 did not affect the
IFN
-alpha/beta response induced by HSV. The results show that the two DC lines provide a convenient tool to study the induction and control of the
IFN
-alpha/beta response, as well as the immunoregulatory role of
IFN
-alpha/beta produced by DC.
...
PMID:Production of interferon-alpha/beta by murine dendritic cell lines stimulated by virus and bacteria. 931 10
We investigated the influence of interferon-alpha (IFN-alpha) on the synthesis of
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) and interleukin-3 (IL-3) by monocytes and activated T helper cells.
IFN
-alpha inhibited the production of
GM-CSF
in unstimulated and lipopolysaccharide (LPS)-activated monocytes to the same extent as was observed in the presence of IL-4. In highly purified CD4+ T cells, which were activated by incubation with immobilized anti-CD3 antibody and anti-CD28,
IFN
-alpha reduced production of
GM-CSF
to 47%. In contrast,
GM-CSF
production in activated T cells was unaffected by exogenously added IL-4. The production of IL-3 by T helper cells was significantly inhibited by
IFN
-alpha as well. IL-3 production by CD3/CD28-stimulated T helper cells was exclusively enhanced by IL-4. The exogenous addition of IL-4 led to a highly significant increase of IL-3 levels in T cell supernatants to 231% of control cultures (range 137%-605%), whereas other T cell-derived cytokines, such as IFN-gamma and IL-10, failed to influence IL-3 release. The differential role of IL-4 in IL-3 production was confirmed by the addition of anti-IL-4 antibodies to CD3/CD28-stimulated T cells. Neutralizing anti-IL-4 antibody caused a drastic reduction of IL-3 synthesis by activated T cells, whereas
GM-CSF
production was independent of neutralization of endogenous IL-4. These experiments define
IFN
-alpha as an inhibitory substance for the production of hematopoietic growth factors by activated immune cells. The influence of IL-4 on cytokine synthesis appears to be cell type specific, thus revealing a differential stimulatory effect on IL-3 production.
...
PMID:Hematopoietic growth factors are differentially regulated in monocytes and CD4+ T lymphocytes: influence of IFN-alpha and interleukin-4. 950 60
Patients with chronic myelogenous leukemia (CML) who achieve a major cytogenetic remission when treated with interferon-alpha (IFN-A) have a survival advantage when compared to patients with no cytogenetic response. We investigated the effect of combining
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) with
IFN
-A in the cytogenetic response of patients with minor responses to
IFN
-A alone. CML patients were eligible if they had shown sensitivity to
IFN
-A as determined by achievement of a hematologic or cytogenetic response, but failed to achieve or lost a major cytogenetic response after a minimum of 12 months of therapy with
IFN
-A alone. Patients received
GM-CSF
30 microg/m2 daily, subcutaneously and the dose was escalated to 60 microg/m2 if tolerated.
IFN
-A was continued at the same dose being received by the patient and escalated when possible. Fourteen evaluable patients were included, 13 in chronic phase and one in accelerated phase. The best response prior to
GM-CSF
was a transient major cytogenetic response in two patients (14%), minor cytogenetic response in nine (64%), and complete hematologic response in three (22%). The median time on
IFN
-A prior to the start of
GM-CSF
was 39 months (range 12-72 months). Four patients achieved a significant cytogenetic response, including two complete (14%) and two partial (14%) cytogenetic remissions during therapy. One partial cytogenetic remission converted to complete shortly after therapy was discontinued. Two other patients had a significant reduction in the percentage of Philadelphia chromosome-positive metaphases. The dose of
IFN
-A could be escalated in half of the patients treated. No toxicity could be attributed to the addition of
GM-CSF
. We conclude that the addition of
GM-CSF
to the treatment with
IFN
-A in CML patients who are sensitive to
IFN
-A alone but fail to achieve a major cytogenetic response may be beneficial in some patients and should be further investigated.
...
PMID:GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. 963 11
Human endothelium is capable of expressing a variety of molecules, including cytokines and growth factors, critical to inflammation. This aspect of coronary endothelium has not been studied in detail. In this study, we report, for the first time, expression of multifunctional cytokines by human coronary artery endothelial cells (HCAEC) and their regulation by inflammatory cytokines and glucocorticoids. We also compared expression of cytokine transcripts in two additional cell lines derived from pulmonary artery (HPAEC) and umbilical vein (HUVEC) endothelium. HCAEC expressed transcripts for interleukin 5 (IL-5), IL-6, IL-8, and monocyte chemotactic protein-1 (MCP-1) constitutively. Induction of IL-1alpha, IL-6,
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
), and MCP-1 was seen following treatment with TNFalpha. We found no expression of IL-1RA, IL-2, IL-4, IL-13, TNF-alpha, or IFN-gamma in HCAEC. IL-1beta and TNF-alpha synergistically induced IL-6 and
GM-CSF
and additively induced IL-8 and MCP-1 production, while IL-2, IL-10,
IFN
-alpha, and IFN-gamma had little or no additional effects. Interestingly, no IL-1alpha or IL-5 protein product was found even after maximal stimulation of HCAEC. No significant differences were seen in the profile of cytokine genes expressed by HCAEC, HPAEC, or HUVEC. Glucocorticoids inhibited IL-8 production from all three cell lines. This study demonstrates that human coronary endothelial cells are capable of expressing a wide variety of multifunctional cytokines which may be of relevance to vascular inflammation.
...
PMID:Multifunctional cytokine expression by human coronary endothelium and regulation by monokines and glucocorticoids. 965 19
The diverse roles of interferon-alpha (IFN-alpha) in regulating the immune response to infectious agents suggested that it might affect dendritic cell (DC) development. Peripheral blood mononuclear cells cultured with
IFN
-alpha and
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) developed a dendritic morphology and expressed high levels of the class I and II human leukocyte antigens (HLA), B7 co-stimulatory molecules, adhesion proteins, and CD40. Elevated DC expression of B7-2 and HLA-DR was observed with increasing
IFN
-alpha concentrations up to 5000 U/mL. The effects of
IFN
-alpha on DC immunophenotype were not reversed by adding neutralizing antibodies against interleukin-4 (IL-4) or tumor necrosis factor alpha to the cell cultures or by eliminating lymphocytes from the cultures. The addition of
IFN
-alpha to cultures containing optimal concentrations of IL-4 and
GM-CSF
significantly increased the B7-2 and HLA-DR levels above those present on DCs grown in two cytokines. The DCs generated with
IFN
-alpha and
GM-CSF
were potent antigen-presenting cells in allogeneic mixed leukocyte reactions. They also were capable of taking up, processing, and presenting tetanus toxin to autologous T lymphocytes. These results demonstrate an important role for
IFN
-alpha in the generation of DCs with potent antigen-presenting capabilities from peripheral blood monocytes.
...
PMID:Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. 973 63
Dendritic cells (DCs) are professional antigen-presenting cells (APCs), and classical DCs, such as Langerhans cells (LCs) or interdigitating DCs (IDCs) are known to be the most potent stimulators of T lymphocytes. Earlier, several groups described the generation of DCs from monocytes, starting with peripheral blood mononuclear cells (PBMCs), adherent cells or magnetic bead-purified CD14+ cells. Although modifications of the original protocols have already been described, some questions relevant to clinical application and basic studies have not yet been addressed.
Granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) and interleukin-4 (IL4) appear to be necessary, but are not sufficient for the differentiation of monocyte-derived dendritic cells (MoDCs), as indicated by the failure to generate such cells under serum-free conditions. Using adherence purified monocytes, we first investigated the amount of
GM-CSF
and IL4 required for the differentiation of DCs. Consecutive kinetic studies during the differentiation period were designed to demonstrate how monocytes acquire the phenotype and function of DCs. The results showed that small amounts of
GM-CSF
and IL4 were required to generate MoDC which acquired their phenotype and function within 4 days. IL13 may substitute for IL4, whereas IL10, TNF alpha or
IFN
gamma inhibited the generation of MoDCs.
...
PMID:Development of accessory phenotype and function during the differentiation of monocyte-derived dendritic cells. 985 13
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>